|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-3-20
|
|
pubmed:abstractText |
The long-term effects of the angiotensin-receptor blocker candesartan, the angiotensin-converting enzyme inhibitor enalapril or their combination have been incompletely studied in a large cohort of patients with heart failure not treated with beta-blockers. The objective of this study was to investigate the changes in neurohormones and LV volumes and ejection fraction in patients treated with enalapril, candesartan, or enalapril plus candesartan without concomitant beta-blocker therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aldosterone,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Enalapril,
http://linkedlifedata.com/resource/pubmed/chemical/Endothelin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Natriuretic Peptide, Brain,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/candesartan,
http://linkedlifedata.com/resource/pubmed/chemical/pro-brain natriuretic peptide (1-76)
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1753-9447
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
113-21
|
|
pubmed:meshHeading |
pubmed-meshheading:19299427-Aged,
pubmed-meshheading:19299427-Aldosterone,
pubmed-meshheading:19299427-Angiotensin II,
pubmed-meshheading:19299427-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:19299427-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:19299427-Benzimidazoles,
pubmed-meshheading:19299427-Double-Blind Method,
pubmed-meshheading:19299427-Drug Therapy, Combination,
pubmed-meshheading:19299427-Enalapril,
pubmed-meshheading:19299427-Endothelin-1,
pubmed-meshheading:19299427-Female,
pubmed-meshheading:19299427-Heart Failure,
pubmed-meshheading:19299427-Humans,
pubmed-meshheading:19299427-Male,
pubmed-meshheading:19299427-Middle Aged,
pubmed-meshheading:19299427-Natriuretic Peptide, Brain,
pubmed-meshheading:19299427-Norepinephrine,
pubmed-meshheading:19299427-Peptide Fragments,
pubmed-meshheading:19299427-Radionuclide Angiography,
pubmed-meshheading:19299427-Stroke Volume,
pubmed-meshheading:19299427-Tetrazoles,
pubmed-meshheading:19299427-Treatment Outcome,
pubmed-meshheading:19299427-Ventricular Function, Left
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
|
|
pubmed:affiliation |
Research Center, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada. m_white@icm-mhi.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
